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Abstract
Aims/hypothesis In type 2 diabetes mellitus, heart failure is a frequent, potentially fatal and often forgotten complication.
Glucose-lowering agents and adjuvant therapies modify the risk of heart failure.We recently reported that 7.8 years of intensified
compared with conventional multifactorial intervention in individuals with type 2 diabetes and microalbuminuria in the Steno-2
study reduced the risk of cardiovascular disease and prolonged life over 21.2 years of follow-up. In this post hoc analysis, we
examine the impact of intensified multifactorial intervention on the risk of hospitalisation for heart failure.
Methods One hundred and sixty individuals were randomised to conventional or intensified multifactorial intervention, using
sealed envelopes. The trial was conducted using the Prospective, Randomised, Open, Blinded Endpoints (PROBE) design. After
7.8 years, all individuals were offered intensified therapy and the study continued as an observational follow-up study for an
additional 13.4 years. Heart-failure hospitalisations were adjudicated from patient records by an external expert committee
blinded for treatment allocation. Event rates were compared using a Cox regression model adjusted for age and sex.
Results Eighty patients were assigned to each treatment group. Ten patients undergoing intensive therapy vs 24 undergoing
conventional therapy were hospitalised for heart failure during follow-up. The HR (95% CI) was 0.30 (0.14, 0.64), p = 0.002 in
the intensive-therapy group compared with the conventional-therapy group. Including death in the endpoint did not lead to an
alternate overall outcome; HR 0.51 (0.34, 0.76), p = 0.001. In a pooled cohort analysis, an increase in plasma N-terminal pro-B-
type natriuretic peptide (NT-proBNP) during the first two years of the trial was associated with incident heart failure.
Conclusions/interpretation Intensified, multifactorial intervention for 7.8 years in type 2 diabetic individuals with
microalbuminuria reduced the risk of hospitalisation for heart failure by 70% during a total of 21.2 years of observation.
Trial registration: ClinicalTrials.gov NCT00320008.
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Abbreviations
ARB Angiotensin II receptor blocker
CIF Cumulative incidence function
CVD Cardiovascular disease
DPP-4 Dipeptidyl peptidase 4
EF Ejection fraction
GLP-1 Glucagon-like peptide 1
MI Myocardial infarction
NT-proBNP N-terminal pro-B-type natriuretic peptide
SGLT-2 Sodium–glucose cotransporter 2
SHR Sub-distribution hazard ratio
u-AER Urinary albumin excretion rate
Introduction
Individuals with type 2 diabetes mellitus are at a high risk of
developing congestive heart failure, having a relative risk at
least twice as high as individuals without diabetes, especially
when urinary albumin excretion rate (u-AER) is elevated [1].
Heart failure is a serious complication in type 2 diabetes, with
a median survival from diagnosis of 3.5 years [2] and a 5-year
mortality rate of 75% [3]. The prognosis of individuals with
type 2 diabetes and heart failure is worse than that of heart-
failure patients without diabetes mellitus [4].
Despite the increased risk and unfavourable prognosis,
heart failure in type 2 diabetes traditionally has been sparsely
reported in cardiovascular outcomes trials for glucose-
lowering drugs [5, 6]. Recent trials, however, have an in-
creased focus on heart failure, but with no consensus between
studies or specific guidance from regulatory bodies [7, 8] in
the methodology used to define prevalent and incident heart
failure, increasing the risk of bias.
Congestive heart failure in diabetes mellitus may be divid-
ed into a primary form termed metabolic or diabetic cardio-
myopathy, and a secondary form predominantly caused by
coronary ischaemia [9–12]; however, distinct definitions that
can be used to differentiate do not exist. Causal factors for the
development of primary heart failure include hypertension,
fluid overload and possibly substrate overload, causing accu-
mulation of intracellular fat and subsequent reduced contrac-
tility of cardiomyocytes [12].
In the Steno-2 study, we compared conventional multifac-
torial management of patients with type 2 diabetes and
microalbuminuria (24 h urinary albumin excretion 30–
300 mg) with intensified multifactorial intervention targeting
known modifiable risk factors with individualised lifestyle
intervention and tailored polypharmacy [13–15] at a
specialised diabetes clinic. After 3.8 years of intervention,
patients who received intensified treatment had a reduction
in the hazard of microvascular complications of around 50%
[13]; after 7.8 years of intervention, a 53% reduction was seen
in cardiovascular endpoints in the arm that was allocated to
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intensified intervention [14]. At this point, the formal
randomisation was neutralised and all patients were offered
intensified treatment as in the original intensive-therapy arm
and the trial continued as an observational follow-up study.
Five years after the end of the trial (in total 13.3 years of
follow-up), we reported a 46% reduction in total mortality of
patients in the arm originally allocated the intensive interven-
tion [15]. We have also recently, in a 21.2-year follow-up after
trial initiation, demonstrated that the intensified multifactorial
approach increased life length with a median of 7.9 years, a
life gain that was matched by time free of incident ischaemic
heart disease of 8.1 years [16]. During the same period, pro-
gression in nephropathy and loss of kidney function was di-
minished, which led to a reduction in the risk of end-stage
renal disease that did not fulfil the pre-specified statistical
significance definition, however (p = 0.061) [17].
In the present post hoc analysis, we report the 21.2-year
risk of developing heart failure in patients with type 2 diabetes
and microalbuminuria, who were allocated conventional mul-
tifactorial care or intensified multifactorial care for a trial pe-
riod of 7.8 years.
Methods
The detailed protocol for patient inclusion, randomisation and
intervention, as well as for anthropometric, clinical and bio-
chemical measurements, has been reported previously [13].
The protocol for the follow-up trial was in accordance with
the declaration of Helsinki and approved by the local ethics
committee (Ethics Committee, Capital Region of Denmark;
protocol ID number: H-KA-99035-GS, add. 41104) and by
the Danish Data Protection Agency (J.Nr. 2015-41-4042)
and the trial was registered at ClinicalTrials.gov, number
NCT00320008. All participants gave their informed consent
upon randomisation and confirmed that on follow-up visits.
Patients
One hundred and sixty Danish patients with type 2 diabetes and
microalbuminuria were randomised from year 1993, using
sealed envelopes, to either conventional or intensified multifac-
torial intervention. Individualswere followed for up to 21.2 years
(Fig. 1). The trial was conducted using the Prospective,
Randomised, Open, Blinded Endpoints (PROBE) design.
Intervention
The treatment regimen in both randomisation groups was tar-
get driven, with targets described in Table 1. In the conven-
tional arm, targets followed national recommendations at all
times. The intensive arm had stricter glycaemic, lipid and
blood pressure targets, and received ACE inhibitors and
aspirin therapy. In order to achieve targets, means of regula-
tion were applied in a sequential manner starting with lifestyle
modification including weight loss, smoking cessation and
increased physical activity with subsequent addition of which-
ever pharmacological agent(s) were needed to achieve the
specific targets.
Endpoint definitions and data
The primary endpoint of this current follow-up study was
hospitalisation with congestive heart failure. The secondary
endpoints were time-to-first-event of composites of heart fail-
ure or cardiovascular death and of heart failure or all-cause
death. Individuals were followed by in-trial study visits after
approximately 2, 4, 8, 13 and 21 years after randomisation
(Fig. 1). At these visits, patients had a comprehensive screen-
ing for micro- and macrovascular complications performed as
described in [16].
Heart failure was defined as described in electronic supple-
mentary material (ESM) Methods, including prespecified
criteria for symptoms, signs and treatment initiated or intensi-
fied. Outcome data were extracted from patient records and
adjudicated by an external expert committee that was blinded
to treatment allocation. Mortality data were collected from the
Danish Civil Registry.
Baseline ejection fraction (EF) was calculated using the
modified Quinones formula [18]. We were not able to correct
for apical movement, resulting in a likely overestimation of
baseline EF. No individuals had, however, any symptoms of
heart failure at baseline, thus we assume the effect to be equal
in the two treatment groups of patients.
Statistical methods
Baseline characteristics were compared using a t test for data
with Gaussian distribution and the Mann–Whitney U test for
data with a non-Gaussian distribution. Time-to-event analyses
were conducted using a Cox proportional hazards model with
treatment as a covariate and illustrated using cumulative inci-
dence function (CIF) curves. The primary analyses were ad-
justed for age and sex. Furthermore, a model adjusted for
BMI, plasma N-terminal pro-B-type natriuretic peptide (NT-
proBNP), EF, systolic blood pressure, HbA1c, u-AER and
GFR measured by 51Cr-EDTA clearance (corrected for body
surface area [19]) was applied with a stepwise backward elim-
ination approach, with a threshold for staying in the model of
α = 0.10. Proportional hazards were checked by visual inspec-
tion of CIF curves. Stepwise backward elimination was cho-
sen to reduce the risk of overfitting the model. We performed
the Cox regressions without elimination of variables as sensi-
tivity analyses.
A number of exploratory analyses were carried out to con-
firm the validity of the results: in order to investigate the
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Post-trial follow-up assessment (n=56)  
Lost to follow-up: n=24
Died: 24
Long term follow-up assessment (n=42) 
Lost to follow-up: n=38  
Died: 38
Allocated to intensive treatment (n=80)
Assessed for microvascular complications 
(n=76)  
Lost to follow-up: n=4 
Died: 4
Assessed for macrovascular complications 
(n=67) 
Lost to follow-up: n=13
Died: 13
Post-trial follow-up assessment (n=40) 
Lost to follow-up: n=40
Died: 40
Long term follow-up assessment (n=24)  
Lost to follow-up: n=56
Died: 55 
Emigrated: 1 
Randomised (n=160)
Allocated to conventional treatment 
(n=80) 
Assessed for microvascular complications 
(n=78)  
Lost to follow-up: n=2
Died: 2
Assessed for macrovascular complications 
(n=63)
Lost to follow-up: n=17
Died: 17
Interventional part of study ended; 
all patients offered intensive treatment in 2001
1993
2001
2006
2014
1997
Fig. 1 CONSORT diagram
showing patient flow throughout
the trial. The first 7.8 years were
the active intervention period,
after which time the
randomisation was neutralised
and continued as a post-trial
observational follow-up study
with all remaining patients being
offered the same treatment as in
the original intensive-therapy
group
Table 1 Treatment targets for treatment groups
Intensive Conventional
1993–1999 2000–2001 1993–1999 2000–2001
Systolic blood pressure (mmHg) <140 <130 <160 <135
Diastolic blood pressure (mmHg) <85 <80 <95 <85
HbA1c (%) <6.5 <6.5 <7.5 <6.5
HbA1c (mmol/mol) <48 <48 <58 <48
Fasting serum total cholesterol (mmol/l) <4.9 <4.5 <6.5 <4.9
Fasting serum triacylglycerol (mmol/l) <1.7 <1.7 <2.2 <2.0
Treatment with ACE inhibitor irrespective of BP Yes Yes No Yes
Aspirin therapy
Known ischaemia Yes Yes Yes Yes
Peripheral vascular disease Yes Yes No No
No known vascular disease No Yes No No
The conventional-therapy group was at all times treated with targets as least as strict as recommended in national guidelines. Aspirin treatment was
initiated if any of the indication criteria were met. The mean intervention duration was 7.8 years and thereafter all patients were offered treatment similar
to that of the original intensive-therapy group
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difference in distribution of primary and secondary heart-
failure events between groups, and to evaluate the impact of
interventions on each type, we used a competing-risks regres-
sionmodel (Fine and Gray [20]) to assess competing risk from
myocardial infarction (MI) and from death in an analysis
where death was not included in the endpoint. We considered
the cases where MI occurred before a hospitalisation for heart
failure as secondary heart failure. Estimates were, in these
analyses, reported as a sub-distribution hazard ratio (SHR)
with 95% CIs. In addition, we performed sensitivity analyses
for the primary and secondary outcomes excluding baseline
EF from the further-adjusted Cox regressions of primary and
secondary outcomes. These analyses were carried out because
of the observation that baseline EF was missing for 15 indi-
viduals (9.4%) (five in the intensive-therapy group; ten in the
conventional-therapy group). We also investigated whether
the change in plasma NT-proBNP and u-AER values during
the first two years of intervention was associated with the
primary and secondary outcomes by adding the delta value
divided into tertiles to the further-adjusted Cox regression.
Numerical results are presented followed by 95% CIs in
brackets. Significance level was set at α = 0.05. Statistical
analyses were performed using STATA/IC version 15
(StataCorp, College Station, TX, USA).
Results
Baseline patient characteristics are presented in Table 2.
Individuals in the two groups were similar with regards to
anthropometrics, and to clinical and biochemical measures.
No individuals had symptoms or clinical signs (including
echocardiographic evidence) of heart failure at baseline.
Mean levels of plasma NT-proBNP were in the upper range
of the normal interval. All patients had microalbuminuria, but
preserved renal function.
Individuals were followed for up to 21.9 years after base-
line with mean follow-up of 21.2 years for those surviving to
the end of follow-up.
Primary and secondary outcomes
Primary outcome Over the entire study course, ten patients
(13%) in intensive-therapy group developed heart failure vs
24 patients (30%) in the conventional-therapy group. All
events complied with the formal definition of the primary
outcome. The age- and sex-adjusted HR was 0.30 (0.14,
0.64), p = 0.002 in the intensive-therapy group compared with
the conventional-therapy group (Fig. 2). The further-adjusted
(BMI, HbA1c, u-AER, GFR, EF, systolic blood pressure and
NT-proBNP) HR was 0.23 (0.10, 0.54), p = 0.001 with age
(p = 0.017), BMI (p = 0.010) baseline EF (p = 0.032) staying
in the final model as independent covariates along with treat-
ment allocation. Baseline GFR (p = 0.065), u-AER (p =
0.070) and HbA1c (p = 0.077) were all of borderline
significance.
Secondary outcome The secondary outcomes are illustrated in
Fig. 3. Eighteen patients (23%) in the intensive-therapy group
and 35 patients (44%) in the conventional-therapy group
Table 2 Baseline clinical, an-
thropometric and biochemical
data
Baseline 1993
Clinical variable (mean ± SD) Intensive (N = 80) Conventional (N = 80)
Age (years) 54.9 ± 7.2 55.2 ± 7.2
Proportion males (%) 79 70
Diabetes duration (years) median (range) 4 (0; 30) 6 (0; 29)
Systolic BP (mmHg) 146 ± 11 149 ± 19
HbA1c – (mmol/mol)
HbA1c – (%)
68 ± 6
8.4 ± 2.7
73 ± 5
8.8 ± 2.6
BMI (kg/m2) (SD) 29.7 (3.8) 29.9 (4.9)
GFR (ml/min/1.73m2) 116 ± 24 118 ± 25
u-AER (mg/24 h) median (IQR) 78 (61; 120) 69 (47; 113)
Plasma NT-proBNP (pmol/l) median (IQR) 35 (12; 71)a 32 (13; 67)
Plasma NT-proBNP ≥ 100 pmol/l (N [%]) 14 (18)a 16 (20)
Left ventricle EF (SD) 67 (8)b 67 (8)c
a One patient with missing data
b Five patients (9%) with missing data
c Ten patients (12.5%) with missing data
IQR, interquartile range
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reached the secondary endpoint of heart-failure hospitalisation
or death fromCVD, leading to an age- and sex-adjusted HR of
0.38 (0.22, 0.68), p = 0.001. Further adjusted, the HR was
0.31 (0.16, 0.58), p = 0.001. Age (p = 0.001), BMI (p =
0.023) and baseline HbA1c (p = 0.011), EF (p = 0.003) and
GFR (p = 0.011) stayed in the model after elimination and u-
AER (p = 0.084) was of borderline significance.
Forty-one patients (51%) originally allocated to intensified
therapy and 59 patients (74%) allocated to conventional ther-
apy reached the combined endpoint of heart failure or death
from all causes. The HRwas 0.51 (0.34, 0.76), p = 0.001. This
estimate was stable in the further-adjusted model, with age (p
< 0.001), GFR (p = 0.050) and plasma NT-proBNP (p =
0.033) staying in the model in addition to treatment allocation,
and with EF (p = 0.074) and HbA1c (p = 0.090) being of bor-
derline significance.
Exploratory analyses
Competing risks from MI In total, nine individuals in the
intensive-therapy group and 23 in the conventional-therapy
group experienced an MI during the study. Of those, two in
the intensive-therapy group and nine in the conventional-
therapy group experienced MI prior to hospitalisation for
heart failure (Figs 4a, b). The SHR of heart failure controlled
for MI in the competing-risks regression was 0.37 (0.17,
0.78), p = 0.009, meaning that the observed difference in
hospitalisation for heart failure was not explained by the dif-
ference in prior MI between groups. A competing-risks re-
gression using all-cause death as the competing event to heart
failure also confirmed the result with SHR of 0.36, p = 0.008.
Among individuals with incident heart failure, seven
(70%) in the intensive-therapy group and 20 (83%) in
the conventional-therapy group died during follow-up
(Fig. 4). Median time from hospitalisation for heart failure
to death was 2.9 years and did not differ between the two
treatment groups. For MI, the corresponding numbers
were six (67%) patients in the intensive-therapy and 18
(75%) in the conventional-therapy group with median
time from MI to death being 2.1 years (please note that
these numbers differ from the numbers in Figs 4a, b
because there, patients may progress from, e.g., MI to
heart failure and then die subsequently, which is not
possible to control for in the simple analysis described
above).
Sensitivity analyses excluding EF in the Cox regression
Estimates of HR for the primary and the secondary endpoints
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Fig. 2 CIF plot of hospitalisation for heart failure. Dashed line, conven-
tional therapy; solid line, intensive therapy. The unadjusted relative haz-
ard reduction was 69% in the intensive-therapy group. Logrank p = 0.001
a
20
40
60
80
100
C
um
ul
at
iv
e 
in
ci
de
nc
e 
of
 h
ea
rt
 fa
ilu
re
 o
r
ca
rd
io
va
sc
ul
ar
 d
ea
th
 (
%
)
80 74 57 38 29 21Conventional
80 75 65 56 51 40Intensive
Number at risk
0
0
0
4 8 12 16 20
Time (years) since randomisation
b
20
40
60
80
100
C
um
ul
at
iv
e 
in
ci
de
nc
e 
of
he
ar
t f
ai
lu
re
 o
r 
de
at
h 
(%
) 
80 74 57 38 29 21Conventional
80 75 65 56 51 40Intensive
Number at risk
0 4 8 12 16 20
Time (years) since randomisation
Fig. 3 CIF plots of the secondary outcomes. Dashed line, conventional
therapy; solid line, intensive therapy. (a) Heart failure or cardiovascular
death. The unadjusted relative hazard reduction was 61% in the intensive-
therapy group. Logrank p < 0.001. (b) Heart failure or death from all
causes. The unadjusted relative hazard reduction was 48% in the inten-
sive-therapy group. Logrank p = 0.001
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were stable when removing baseline EF from the model (ESM
Table 1). Using Cox regression without elimination of vari-
ables confirmed the results, without any change of HR esti-
mates (ESM Table 2).
The inclusion of plasma NT-proBNP as a dichotomous
variable with a cut-off of 100 pmol/l in the further-adjusted
model instead of as a continuous variable showed a significant
association with heart failure (HR 3.2 for high vs low NT-
proBNP [p = 0.09]) and with heart failure plus all-cause death
(HR for high vs low NT-proBNP 1.9 [p = 0.015]).
Change in plasma NT-proBNP over the first two years of fol-
low-up Change in plasma NT-proBNP during the first two
years was significantly associated with the primary outcome
(in the period from year 2 to 21) in the adjusted Cox regression
model. Individuals (pooled cohort) with changes in the highest
tertile of delta plasma NT-proBNP (i.e. the largest increase)
had a 2.7-fold ([1.19, 5.93], p = 0.018) increased risk of heart
failure as compared with individuals in the lower two tertiles
of change. Individuals (pooled cohort) in the second tertile did
not differ significantly in risk from those in the lowest tertile
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Fig. 4 Transition frequencies from entry to MI, HF and/or death. (a)
Intensive-therapy group and (b) conventional-therapy group: arrows ter-
minate at the event and originate from the original state of the patients.
The black number at the arrow end is the number with the given event
coming from the state at arrow origin. The coloured number in the bottom
right corner is the number of patients not progressing from the given state.
Example: ten intensive-therapy patients developed HF (pale orange box,
Fig. 4a). Eight had no previous MI; two developed HF after previous MI.
One developed MI after HF, six died after HF and three ended the obser-
vation alive with HF. Twenty-seven patients died without prior MI or HF.
In the primary analysis of data from the 21.2 years of follow-up, 26
patients in the intensive-therapy and 29 in the conventional-therapy group
were classified as having died from non-CV causes and 12 vs 26 patients
died from CV causes, respectively. Thirty-seven patients in the intensive-
therapy group and 20 patients in the conventional-therapy group ended
follow-up alive and with no incident HF or MI during follow-up. (c)
Intensive-therapy group and (d) conventional-therapy group: survival
frequencies without MI/HF. Both MI and HF were more frequent in the
conventional-therapy group (b) and the difference in HF was not driven
primarily by increased MI risk. DM2, type 2 diabetes mellitus; HF, heart
failure
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(p = 0.14). Assessing an interaction between change in NT-
proBNP and treatment allocation revealed that this finding
was driven by the conventional-therapy group. In the
conventional-therapy group, individuals with changes in the
higher tertile had a threefold increased risk of heart failure
compared with those in the two lower tertiles (p = 0.030),
whereas this was not the case for the intensive-therapy group
(p = 0.60). Change in plasma NT-proBNP was not associated
with cardiovascular mortality combined with heart failure, but
had a positive correlation with all-cause mortality; HR = 1.86
(1.18, 2.92), p = 0.07 for the highest tertile compared with the
lower two tertiles. These findings were not affected by treat-
ment allocation, but significantly more patients in the conven-
tionally treated therapy group were in the upper tertile of plas-
ma NT-proBNP (32 vs 19; p = 0.041).
In similar analyses, change in albuminuria was not associ-
ated with any of the outcomes (ESM Table 3).
Discussion
Heart failure is a major health issue and a risk factor for early
death and disability in type 2 diabetes. Until now, no trials of
intensified multifactorial intervention in type 2 diabetes have
investigated the potential beneficial effects of this treatment
modality on congestive heart failure. In this post hoc analysis
of outcome data from the Steno-2 randomised trial, we dem-
onstrate that intensified multifactorial treatment in patients
with type 2 diabetes mellitus, microalbuminuria and preserved
baseline EF for 7.8 years reduced the hazard of developing
clinical heart failure by 70% at 21.2 years of follow-up.
Twenty per cent of all patients developed heart failure,
equalling the number of patients experiencing MI (20%),
stroke (22%), amputation (19%) or blindness (19%) [16]
and mortality seemed to be at least as high for patients with
incident heart failure as for patients experiencing an MI. We
also found that the reduction in heart failure was influenced
by, but not dependent on, reduction of ischaemic heart disease
risk. The results were unchanged over multiple sensitivity
analyses including testing for common confounders and com-
peting risk. Our results clearly underline the importance of
applying an intensive, multifactorial approach to the manage-
ment of type 2 diabetes.
In the following studies (all including patients with type 2
diabetes and micro- or macroalbuminuria), heart failure was
more common than other cardiovascular complications: re-
duction of Endpoints in NIDDM with the Angiotensin II
Antagonist Losartan (RENAAL) [21], the Irbesartan
Diabetic Nephropathy Trial (IDNT) [22], the Aliskiren Trial
in Type 2 Diabetes Using Cardiorenal Endpoints
(ALTITUDE) [23] and Microvascular outcomes in the Heart
Outcomes Prevention Evaluation Study (MICRO-HOPE)
[24]. However, the Steno-2 study had significantly longer
follow-up, thus allowing more time for atherosclerosis pro-
gression. It is unlikely that the risk reductions seen in the
Steno-2 study are attributable to one single component of
the multifactorial treatment regimen, but rather to the combi-
nation of polypharmacy and lifestyle intervention. The drug
pattern was highly complex (ESM Figs 1, 2), but the use of
ACE inhibitors, angiotensin II receptor blockers (ARBs),
statins and aspirin was more frequent in the intensive-
therapy group, which is probably reflected in our findings.
In particular, we would anticipate the effect of more frequent
use of ACE inhibitors and ARBs to be prominent.
Our findings suggest that diabetes caregivers should pay
attention to early signs and symptoms of congestive heart
failure including left-ventricular dysfunction and, together
with cardiologists, take appropriate actions. Measuring plas-
ma NT-proBNP might be helpful in assessing and monitoring
risk of heart failure since high values or large increments were
strongly associated with heart-failure outcomes and could be
used to guide diabetologists to refer patients for evaluation by
cardiologists. Our findings indicate that the higher risk of heart
failure associated with an increase in NT-proBNP can be mit-
igated by intensified multifactorial intervention. However, ev-
idence that intensive lifestyle improvement may increase NT-
proBNP and the fact that NT-proBNP levels are inversely
related to BMI warrants caution when interpreting our find-
ings regarding NT-proBNP [25, 26].
Glucose-lowering drugs, as well as adjuvant therapies for
diabetes comorbidities, modify the risk of developing heart
failure. In 2009, increased risk of heart failure in diabetic
patients treated with rosiglitazone in the Rosiglitazone
Evaluated for Cardiac Outcomes and Regulation of
Glycaemia in Diabetes (RECORD) trial [27] was reported
and subsequently, the use of dipeptidyl peptidase 4 (DPP-4)
inhibitors also has been flagged as potentially increasing the
risk of heart failure [28]. Although the latter findings have
been questioned [29, 30], the Food and Drug Administration
(FDA) recently added heart-failure warnings to the Summary
ofmedicinal Products Characteristics (SmPC) for all marketed
DPP-4-inhibitors [31]. In contrast, diabetes trials with the so-
dium–glucose cotransporter 2 (SGLT-2) inhibitors
empagliflozin and canagliflozin have demonstrated heart-
failure risk reduction [32–34], whereas diabetes treatment
with GLP-1 receptor agonists seem to have a neutral effect
on the risk of heart failure [35–37]. In addition, the extensive
use of ACE inhibitors [24, 38], ARBs, beta blockers and
statins [39] in type 2 diabetes may modify the risk of heart
failure, although the evidence regarding the latter is weak.
This post hoc analysis has limitations: the Steno-2 study
has a small sample size of 160 individuals and the type 2
diabetes study population with microalbuminuria is selected
as a high-risk patient group. Therefore, the magnitude of risk
reduction we demonstrate here might not be attributable to a
population of lower risk. Furthermore, the sample size leads to
Diabetologia (2018) 61:1724–1733 1731
an inherent risk of committing type 1 statistical errors due to
unaccountable bias. The fact that the results presented in this
paper are in accordance with previously published results re-
garding other manifestations of cardiovascular disease can be
regarded both as a strength and as a weakness, the latter
underlined by the above statement of unmeasurable bias driv-
ing the difference in outcomes between groups.
We do not have complete echocardiographic data available
for the entire patient population and baseline EF was based on
a calculated estimate. Therefore, whether individuals had pre-
served or reduced EF prior to and after hospitalisation is un-
certain. However, recent evidence shows that the prognosis is
independent of EF [3].
In the Steno-2 trial and during trial follow-up, the use of
sulfonylurea drugs was frequent and even between groups
(ESM Fig. 1) and the use of ACE inhibitors and beta blockers
was more frequent in the intensive-therapy group (ESM Fig.
2), but the total exposure to glitazones, DPP-4 inhibitors,
GLP-1 inhibitors and SGLT-2 inhibitors etc. was very limited
(all <5% of patients in each group at each follow-up point).
The effects on heart failure of the above-mentioned drugs that
have been seen in recent large-scale clinical trials of cardio-
vascular outcomes occur on top of the standard of care; in
most current recommendations, the standard of care resembles
the treatment targets for the patients originally allocated to
intensified multifactorial care in the Steno-2 trial.
The significant and meaningful risk reductions reported
here should be seen as a benefit of intervention against tradi-
tional risk factors; the introduction of novel glucose-lowering
drugs with pleiotropic effects, on top of improved glucose
control, that reduce the risk of cardiovascular morbidity and
mortality by other, not presently fully elucidated, mechanisms
should lead to optimism in the field of diabetes care.
In conclusion, our study demonstrated hospitalisation for
heart failure to be a frequent and fatal complication in patients
with type 2 diabetes and microalbuminuria. Intensified multi-
factorial intervention significantly reduced the occurrence of
this outcome.
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